Bioventus (BVS) Change in Accured Expenses (2020 - 2026)

Bioventus (BVS) has 7 years of Change in Accured Expenses data on file, last reported at -$15.4 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 60.7% year-over-year to -$15.4 million; the trailing twelve-month figure through Mar 2026 stood at $3.9 million (up 128.17% YoY), and the FY2025 full-year result was -$19.8 million, down 211.03% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$15.4 million, down from -$4.4 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $29.9 million in Q2 2024 and bottomed at -$39.1 million in Q1 2025.
• The 5-year median for Change in Accured Expenses is $2.3 million (2023), against an average of -$1.5 million.
• The widest annual swing landed in 2022, when Change in Accured Expenses slumped 911.94%; it then surged 186.98% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at $14.3 million in 2022, then sank by 59.53% to $5.8 million in 2023, then surged by 186.98% to $16.6 million in 2024, then plunged by 126.74% to -$4.4 million in 2025, then tumbled by 245.79% to -$15.4 million in 2026.
• The last three Change in Accured Expenses figures came in at -$15.4 million (Q1 2026), -$4.4 million (Q4 2025), and $7.3 million (Q3 2025), per Business Quant data.

Peer Comparison